Clinical and mechanistic role of HDGF in pulmonary hypertension

儿童或成人的肺动脉高压(PH)是一种进行性和致命性疾病，其特征是持续 原因不明的肺动脉压升高。尽管血管扩张药物的数量 增加，仍然有20%-30%的患者没有反应，无反应的人最终预后很差 需要肺移植1-4次。唐氏综合征患者常出现肺动脉高压 并与死亡率的增加有关，特别是在先天性心脏病(CHD)患者中。 科罗拉多大学唐氏综合症诊所，27.6%的患者有肺动脉高压。 肺动脉高压增加唐氏综合征患者的发病率和死亡率，潜在的 疾病负担和增加发展为肺动脉高压风险的特定合并症的作用 在唐氏综合征中还没有完全了解。9一个主要原因，是我们缺乏简单、微创的更多 肺/血管特异性、客观、可重复、可推广且成本较低的PH测量方法 综合症，以改善结果。《HDGF在肺动脉高压中的临床和机制作用》研究 R01HL135114-02由国家心肺血液研究所授予，旨在阐明体外和 高密度脂蛋白生长因子在I组肺动脉高压中的作用及其作为循环的可能性 衡量PAH严重程度、治疗反应和存活率的新指标。 通过家长研究，我们已经与NHLBI PAH生物库建立了合作关系 辛辛那提大学、范德比尔特大学和科罗拉多大学丹佛儿童学院的研究人员 &gt；2100例儿童和成人肺动脉高压(PAH，WHO I组)和正常对照样本 成人和儿童对照，使用定制的多重ELISA检测肝癌衍生生长因子(HDGF)a 肺血管生成蛋白与肺高压存活期和功能预后显著相关(6分钟 步行距离)、10和既往PH生物标志物作为基准，包括标准临床心力衰竭 生物标志物(NTproBNP、ST2、Gal3)、炎症(IL6)和血管生成(血管内皮生长因子和内皮抑素)。内皮抑素 尤其重要，因为它是18A胶原蛋白的血管生成抑制物片段，并且与 与PH患者的生存和功能结局有关，该基因位于21.11号染色体上，尽管成功 在母研究中，它只侧重于世卫组织第一组肺动脉高压，不包括 唐氏综合征患者。因此，考虑到唐氏综合征中PH的发生率和 在生物标记物研究中，迫切需要识别PH诊断/预后生物标记物以改进 唐氏综合征的转归。 总体目标：加强“HDGF在肺动脉高压中的临床和机制作用”研究 利用组件2的包含研究目标增加一个新的唐氏综合征队列用于循环 PH生物标志物分析及其与WHO I组大队列(N=2100)和正常对照的比较 成人(N=110)和儿童(N=165)。

Pulmonary hypertension (PH) in children or adults is a progressive and fatal disease characterized by sustained elevations of pulmonary artery pressure of unknown etiology. Although the number of vasodilator drugs has increased, still 20-30% of patients do not respond and non-responders have a poor prognosis eventually requiring lung transplantation1-4. Pulmonary hypertension is frequently identified in patients with Down syndrome and is associated with increased mortality, especially in patients with congenital heart disease (CHD).5-8 In the University of Colorado Down syndrome clinic, 27.6% of patients had pulmonary hypertension.9 Although pulmonary hypertension increases morbidity and mortality in subjects with Down syndrome, the underlying disease burden and the role of specific comorbidities that increase the risk of developing pulmonary hypertension in Down syndrome are not completely understood.9 A major reason, is we lack simple, minimally invasive more lung/vascular specific, objective, repeatable, generalizable and less expensive measures of PH in Down syndrome to improve outcomes. The study, “Clinical and mechanistic role of HDGF in pulmonary hypertension” R01HL135114-02 awarded from the National Heart Lung and Blood Institute, aims to elucidate the in vitro and in vivo mechanistic role of HDGF in Group I pulmonary artery hypertension and potential as a circulating new measure of PAH severity, therapeutic response and survival. With the parent study we have established collaborations with the NHLBI PAHBiobank at the University of Cinicinnati, Vanderbilt University and Denver Children’s at the University of Colorado, and have assayed >2100 samples from children and adults with pulmonary arterial hypertension (PAH, WHO Group I) and normal adult and pediatric controls, using custom built multiplex ELISAs for hepatoma derived growth factor (HDGF) a pulmonary angiogenic protein that is significantly associated with PH survival and functional outcomes (6 minute walk distance),10 and historical PH biomarkers as benchmarks including the standard clinical heart failure biomarkers (NTproBNP, ST2, GAL3), inflammation (IL6), and angiogenesis (VEGF and endostatin). Endostatin is particularly important as it is an angiogenic inhibitor fragment of collagen 18A, and significantly associated with survival and functional outcomes in patients with PH and located on Chromosome 21.11 Despite the success of the parent study, it is focused only on WHO Group I pulmonary arterial hypertension and did not include patients with Down syndrome. Therefore, considering the incidence of PH in Down syndrome and the paucity of biomarker studies, there is an urgent need to identify PH diagnostic/prognostic biomarkers to improve outcomes in Down syndrome. Overarching objective: To augment the “Clinical and mechanistic role of HDGF in pulmonary hypertension” study using the INCLUDE research objective of Component 2 to add a new Down Syndrome cohort for circulating PH biomarker analysis with and without PH and comparison to a large WHO Group I cohort (N=2100) and normal adults (N=110) and children (N=165).